METX Share Price Performance
Recent METX News & Updates
No updates
ME Therapeutics Holdings Inc. Key Details
Last Reported Earnings
May 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.039
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
ME Therapeutics Holdings Inc. Competitors
About METX
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.
Canadian Market Performance
- 7 Days: -1.7%
- 3 Months: 8.2%
- 1 Year: 18.6%
- Year to Date: 8.7%
Over the last 7 days, the market has dropped 1.7%, driven by a pullback of 2.5% in the Financials sector. In the last year, the market is actually up 19%. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading